Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia

• Published in: American journal of hematology Vol. 92; no. 7; pp. 668 - 673
• Main Authors: Sidana, Surbhi, Rajkumar, S. Vincent, Dispenzieri, Angela, Lacy, Martha Q., Gertz, Morie A., Buadi, Francis K., Hayman, Suzanne R., Dingli, David, Kapoor, Prashant, Gonsalves, Wilson I., Go, Ronald S., Hwa, Yi Lisa, Leung, Nelson, Fonder, Amie L., Hobbs, Miriam A., Zeldenrust, Steven R., Russell, Stephen J., Lust, John A., Kyle, Robert A., Kumar, Shaji K.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.07.2017
• Subjects: Adult; Aged; Aged, 80 and over; Alkylating agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Autografts; Biopsy; Blood diseases; Combined Modality Therapy; Cryoglobulinemia; Cryoglobulinemia - diagnosis; Cryoglobulinemia - mortality; Cryoglobulinemia - therapy; Cryoglobulins; Diagnosis, Differential; Female; Gangrene; Glomerulonephritis; Hematology; Hematopoietic Stem Cell Transplantation - methods; Humans; Immunoglobulin G - blood; Immunoglobulin M - blood; Kaplan-Meier Estimate; Lymphocytes; Lymphoma; Male; Middle Aged; Monoclonal antibodies; Multiple myeloma; Myeloma; Neuropathy; Patients; Phenotype; Plasmapheresis; Purpura; Rituximab; Stem cell transplantation; Steroid hormones; Targeted cancer therapy; Transplantation, Autologous; Treatment Outcome; Ulcers

We describe a series of 102 patients diagnosed from January 1, 1990 to December 31, 2015 with Type 1 monoclonal cryoglobulinemia (MoC). Symptoms were seen in 89 (87%) patients, including: cutaneous symptoms in 64 (63%) patients, with purpura (n = 43, 42%) and ulcers/gangrene (n = 35, 34%) being most...